258
Participants
Start Date
March 31, 2012
Primary Completion Date
March 31, 2013
Study Completion Date
July 31, 2013
lebrikizumab
subcutaneous dose every 4 weeks
lebrikizumab
subcutaneous dose every 4 weeks
lebrikizumab
subcutaneous dose every 4 weeks
placebo
subcutaneous dose every 4 weeks
Nedlands
New York
The Bronx
Great Neck
Rockville Centre
Harrisburg
Easton
Upland
Philadelphia
Blue Bell
Henrico
High Point
Wilmington
Spartanburg
Greenville
Savannah
Albany
Tallahassee
Gainesville
Winter Park
North Palm Beach
Tampa
Ocala
Pell City
Knoxville
Cincinnati
Madison
River Forest
Kansas City
Topeka
Bellevue
Metairie
McKinney
Dallas
Arlington
Fort Worth
San Antonio
San Antonio
El Paso
Wheat Ridge
Centennial
Denver
Colorado Springs
Scottsdale
Scottsdale
Tucson
Albuquerque
Las Vegas
Las Vegas
Los Angeles
Los Angeles
Studio City
Upland
San Diego
Rancho Mirage
Mission Viejo
Fountain Valley
Fullerton
Orange
Bakersfield
Napa
Walnut Creek
Sacramento
Honolulu
Lake Oswego
Portland
Seattle
Waterbury
Bangor
Eugene
Warwick
Lead Sponsor
Genentech, Inc.
INDUSTRY